Evidence map›Paper›PMID 38033504›Full record

ArticleFrontiers in oncology2023

The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients.

Longqing Li, Ye Li, Minxun Lu, Yitian Wang, Zhuangzhuang Li, Xin Hu, Xuanhong He, Taojun Gong, Yi Luo, Yong Zhou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Longqing Li *Department of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Ye Li *Department of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Minxun LuDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Yitian WangDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Zhuangzhuang LiDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Xin HuDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Xuanhong HeDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Taojun GongDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Yi LuoDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Yong ZhouDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Li MinDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Chongqi TuDepartment of Orthopedics, Orthopedics Research Institute, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteosarcoma is a primary malignant bone tumor with a high metastatic potential that accounts for a significant proportion of all bone tumors. The prognosis for patients with metastatic or recurrence disease remains poor. The neutrophil-to-lymphocyte ratio (NLR) has become a potential prognostic biomarker for cancer. Recent evidence suggests that the dynamic changes in neutrophil-to-lymphocyte ratio (NLR) during treatment may be more informative in predicting patient prognosis, but the value of dynamic NLR in osteosarcoma has not yet been determined. Methods: This retrospective study retrospectively analyzed the clinical information of 251 osteosarcoma patients diagnosed and treated in West China Hospital of Sichuan University, explored the impact of baseline NLR and changes in NLR during treatment on the prognosis of osteosarcoma patients, and further combined baseline NLR with Delta NLR to build an NLR staging system. Results: The results showed that both baseline NLR and delta NLR had some predictive ability for the prognosis of osteosarcoma patients (P = 6.90e-4, P = 0.022). Patients with high baseline NLR were more likely to have a decrease in delta NLR (P = 1.24e-10). The NLR stage had a better predictive ability than baseline NLR and delta NLR, and was an independent prognostic factor for overall survival in osteosarcoma patients HR: 2.456 (1.625-3.710) (P = 1.97e-05). Conclusion: NLR has value in continuous monitoring, and continuous monitoring of NLR can better predict the survival of osteosarcoma patients compared to baseline NLR.

Indexed as

neutrophils-to-lymphocytes ratioosteosarcomaprognosisrisk modelsurvival

Identifiers

PMID38033504
PMCPMC10682781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.